Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RSV LID deltaM2-2 1030s

Next Previous
Drug Profile

RSV LID deltaM2-2 1030s

Alternative Names: LID ΔM2-2 1030s; RSV LID ΔM2-2 1030s; RSV LID/ΔM2-2/1030s

Latest Information Update: 29 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Class Attenuated vaccines; DNA vaccines; Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 29 Jan 2025 RSV LID deltaM2-2 1030s is still in phase I development in Respiratory-syncytial-virus-infections (In infants, Prevention) in USA (Intranasal) (NCT04520659)
  • 28 Mar 2022 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In infants, Prevention) in USA (Intranasal, Drops)
  • 20 Aug 2020 National Institute of Allergy and Infectious Diseases and Sanofi plan a phase I trial in Respiratory syncytial virus infections (Prevention, In infants) in USA (NCT04520659)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top